Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment

Ferrari, Serge Livio; Butler, Peter W; Kendler, David L; Miller, Paul D; Roux, Christian; Wang, Andrea T; Huang, Shuang; Wagman, Rachel B; Lewiecki, E Michael

doi:10.1210/jc.2019-00271

Scientific article

English

Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment

ContributorsFerrari, Serge Livio; Butler, Peter W; Kendler, David L; Miller, Paul D; Roux, Christian; Wang, Andrea T; Huang, Shuang; Wagman, Rachel B; Lewiecki, E Michael

Published inJournal of Clinical Endocrinology and Metabolism, vol. 104, no. 8, p. 3450-3461

Publication date2019

Abstract

CONTEXT: Evidence for further nonvertebral fracture (NVF) reductions with long-term antiresorptive therapy in osteoporosis is lacking. OBJECTIVE: To evaluate NVF risk reduction in subjects receiving ≤10 years of denosumab treatment. DESIGN: Phase 3, randomized, placebo-controlled, 3-year Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial (NCT00089791) and its open-label 7-year extension (NCT00523341).

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Génétique des ostéoporoses (544)

Citation (ISO format)

FERRARI, Serge Livio et al. Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment. In: Journal of Clinical Endocrinology and Metabolism, 2019, vol. 104, n° 8, p. 3450–3461. doi: 10.1210/jc.2019-00271

Article (Published version)

Identifiers

PID : unige:123828
DOI : 10.1210/jc.2019-00271
PMID : 31125092

Additional URL for this publicationhttps://academic.oup.com/jcem/article/104/8/3450/5497103

Journal ISSN0021-972X

329views

1downloads

Creation07/26/2019 10:56:00 AM

First validation07/26/2019 10:56:00 AM

Update time03/15/2023 6:06:06 PM

Status update03/15/2023 6:06:05 PM

Last indexation10/31/2024 4:24:21 PM

Archive ouverte UNIGE

Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment

Technical informations